Editas Medicine, Inc. EDIT R2KR3KPHARMA
Company Overview
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Why Investors Should Care
Revenue has grown at a 23.5% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $40.52M (+25.4% YoY); net profit $-160.06M.
- Trailing 12 Months Year-on-year growth — revenue -39.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 23.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 23.52% |
| 1 Year: | -39.20% |
Stock Price Performance
| 1 Year: | +4.87% |
| 6 Months: | +61.50% |
| 3 Months: | +19.19% |
| 1 Month: | +11.38% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.49 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 23.5% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EDIT Editas Medicine, Inc. R2KR3KPHARMA | 3.23 | -4.89 | $496.06M | 0.00% | -114.06% | - | 23.52% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 3.93M | 7.37M | 14.52M | 6.12M | 2.07M | 2.33M | 3.85M | 12.28M | 5.72M | 10.75M | 62.84M | 11.42M | 6.50M | 379.00K | 6.20M | 6.77M | 6.36M | 42.00K | 9.85M | 2.89M | 5.34M | 1.14M | 513.00K | 61.00K | 4.66M | 3.58M | 7.54M | 2.83M | 11.89M |
| Operating Income | -10.40M | -7.38M | - | -17.84M | -19.20M | -21.16M | - | -30.63M | -26.11M | -26.75M | - | -31.56M | -39.66M | -16.26M | -26.25M | -31.26M | -35.65M | -34.59M | - | -46.62M | -31.34M | 8.99M | - | -56.88M | -55.40M | -39.25M | -50.75M | -54.23M | -57.52M | -50.96M | -44.09M | -50.16M | -66.99M | -71.90M | -65.67M | -76.16M | -51.54M | -24.55M | -25.00M | -18.55M |
| Net Income | -47.57M | -7.41M | -12.63M | -17.75M | -19.04M | -21.02M | -39.38M | -31.10M | -26.44M | -26.60M | -36.19M | -30.94M | -38.72M | -15.24M | -25.05M | -29.25M | -33.79M | -32.94M | -37.77M | -37.72M | -23.57M | 7.82M | -62.50M | -56.73M | -55.26M | -39.08M | -50.52M | -53.45M | -55.73M | -49.04M | -40.29M | -45.02M | -61.95M | -67.61M | -62.14M | -76.09M | -53.23M | -25.12M | -24.98M | -18.23M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.66 | - | -0.69 | -0.43 | 0.12 | -1.00 | -0.86 | -0.81 | -0.57 | -0.74 | -0.78 | -0.81 | -0.71 | -0.56 | -0.55 | -0.76 | -0.82 | -0.75 | -0.92 | -0.63 | -0.28 | -0.26 | -0.15 |
| R&D Expense | 7.28M | 3.85M | - | 8.88M | 10.43M | 10.83M | - | 19.02M | 17.32M | 20.40M | - | 21.30M | 32.72M | 17.44M | - | 15.84M | 23.57M | 22.70M | - | 34.57M | 28.01M | 33.92M | - | 41.94M | 33.75M | 29.27M | 37.98M | 43.66M | 41.33M | 37.80M | 29.78M | 40.51M | 48.79M | 54.21M | 47.64M | 26.59M | 16.18M | 19.77M | 17.60M | 20.18M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 6.05M | 13.73M | 31.94M | 20.53M | 90.73M | 25.54M | 19.71M | 78.12M | 32.31M | 40.52M |
| Operating Income | -12.72M | -35.31M | -97.19M | -119.93M | -113.73M | -140.92M | -134.84M | -193.15M | -225.95M | -169.18M | -251.15M | -160.01M |
| Net Income | -13.69M | -72.90M | -97.18M | -120.32M | -109.95M | -133.75M | -115.98M | -192.50M | -220.43M | -153.22M | -237.09M | -160.06M |
| Diluted EPS | - | - | - | - | - | -2.68 | -1.98 | -2.85 | -3.21 | -2.02 | -2.88 | -1.80 |
| R&D Expense | 5.07M | 18.85M | 56.98M | 83.16M | 90.65M | 96.90M | 158.00M | 142.51M | 174.96M | 177.65M | 199.25M | 89.95M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 149.36M | 229.18M | 373.26M | 420.39M | 508.88M | 572.60M | 677.48M | 514.32M | 499.15M | 341.59M | 186.53M |
| Total Equity | -1.76M | -15.29M | -83.11M | 134.61M | 208.08M | 236.16M | 262.44M | 393.59M | 553.64M | 360.68M | 349.10M | 134.27M | 27.29M |
| Cash & Equivalents | 2.01M | 10.62M | 143.18M | 185.32M | 146.63M | 134.78M | 238.18M | 139.68M | 203.52M | 141.52M | 123.65M | 131.54M | 146.65M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | 0 | 52.43M | 53.60M |
| Total Liabilities | - | - | 32.56M | 94.58M | 165.18M | 184.22M | 246.45M | 179.02M | 123.84M | 153.64M | 150.06M | 207.31M | 159.25M |
| Current Liabilities | - | - | 6.92M | 33.08M | 36.71M | 35.90M | 59.96M | 58.21M | 46.88M | 60.11M | 63.22M | 77.22M | 46.25M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -5.44M | -50.25M | -9.42M | -45.71M | -40.67M | -179.84M | - | -177.35M | -132.18M | -210.28M | -165.24M |
| Investing Cash Flow | - | -1.43M | -3.47M | -183.81M | -53.09M | 12.25M | -140.52M | - | 114.07M | -3.73M | 162.15M | 138.67M |
| Financing Cash Flow | - | 139.39M | 97.16M | 154.53M | 86.94M | 131.82M | 224.12M | - | 1.28M | 118.04M | 56.03M | 40.47M |
| Capital Expenditure | -1.22M | -1.43M | -3.49M | -2.06M | -4.75M | -6.17M | -7.16M | - | -4.12M | -4.72M | -8.83M | -607.00K |
| Free Cash Flow | - | -6.87M | -53.74M | -11.48M | -50.46M | -46.84M | -187.00M | - | -181.47M | -136.90M | -219.11M | -165.85M |
| Net Change in Cash | - | - | - | - | - | - | - | - | -62.00M | -17.87M | 7.89M | 13.90M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -1,605.6% | -873.6% | -356.1% | -686.4% | -148.6% | -756.1% | -1,146.3% | -216.6% | -777.2% | -394.9% |
| Net Margin % | - | - | -1,605.5% | -876.5% | -344.3% | -651.4% | -127.8% | -753.6% | -1,118.3% | -196.1% | -733.7% | -395.0% |
| ROE % | 89.5% | 87.7% | -72.2% | -57.8% | -46.6% | -51.0% | -29.5% | -34.8% | -61.1% | -43.9% | -176.6% | -586.6% |
| ROCE % | - | -24.8% | -49.6% | -35.6% | -29.6% | -31.4% | -26.2% | -30.6% | -49.7% | -38.8% | -95.0% | -114.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | TCG Crossover Management, LLC | 7.23% | 11.11M | $35.11M |
| 2 | Blackrock Inc. | 6.90% | 10.59M | $33.46M |
| 3 | Commodore Capital Lp | 5.79% | 8.89M | $28.09M |
| 4 | RA Capital Management, L.P. | 5.79% | 8.89M | $28.09M |
| 5 | Adar1 Capital Management, LLC | 5.79% | 8.89M | $28.09M |
| 6 | Vanguard Capital Management LLC | 4.00% | 6.14M | $19.41M |
| 7 | Paradigm Biocapital Advisors LP | 3.64% | 5.59M | $17.65M |
| 8 | Opaleye Management Inc. | 2.51% | 3.86M | $12.20M |
| 9 | Vanguard Portfolio Management LLC | 2.34% | 3.60M | $11.37M |
| 10 | Woodline Partners LP | 2.32% | 3.56M | $11.24M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EDIT
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPbmUybnRKZGZlTnZ3QTluSTFDYkpYNVhPMW1PZWFEUFZHdDc0MEFxNGU1cFRydjNZVHoyT2Nfald3ZzJUVzg2SHRGQkVNZU1ua3VpRUQyMUZySEVFOGs0LWZDRTFCSUd4OFQtZ3FwWWZtZkl3SEpaQ2pGMU1ZRWxadDFjYkY0SnpIcWNPZW…
Editas Medicine (NASDAQ: EDIT) CEO sells 5,124 shares in tax-plan trade - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNR2Y0ZkVxblN0MEJ5YXNHS21LWU9tMnk5blZuZXZOQm14MEJqMkFHc2wxU0dTdTVsd25WeGRxcXBWQUFKY0w0OGhUWHhwenFSZGl6NkZ4amdDTlhaQ3kxVndlcUR6QTNzaWJKYkNwNzV0OWNYeksyVEZ6ZTA5My1mZmZlTEs2blhTQ091RE…
Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,124 Shares of Stock - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxONzZMWkNwazh6Y3lucGtrejhRY3VZcjFsMHFFMkVtUHAtMHc2MG5iQW5UWnVqaU8xNEZ2QndGQjZLcHRJcGs4b3AyRVptc0NBRHF2cktsSDJCdDJkSDVZRnE3eGQ0dkVBaGtvNXl6LU9HUVNCVTZhQ2JKdTc0TkZqTXpfOS1RWlpBWEZfTV…
EDIT Stock Price, Quote & Chart - ChartMill
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBKT0JtOHhYWFZFdHEyTlFXcFMtR3lpc0I0YjNyZGhuRG9NUEdNWUh1SHJjaU85dVhIT3Jrb01OSkg0b1BuVUZFVHBNWEFVdTIxdG1DR2V0bjBHSTVfbDFR?oc=5" target="_blank">EDIT Stock Price, Quote & Chart</a>&nbs…
EDIT - Editas Medicine Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBHakFfYTdzblZGZmtwWHRhbjhlOXUzTGJmVF9VWmUyNHFuODdlY2g2ZmhKV2QwY3MtTTJJb2QyaWJ5ZDJYMFE?oc=5" target="_blank">EDIT - Editas Medicine Inc Stock Price and Quote</a> <font co…
$EDIT stock is down 10% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOZHd5bWVndW9QeUl2SzN3V3BETFh1NGhLWUwtSHozZGJqXzdGcUlWU05MNEhGd2xuZ2pBNUhGNFEwUWtUR0RTbVJYUGh3SFkweS1la3NxeEo4cUpPbVhvei1lcHFidTJKdzJjWDZwV3JhNi1uWjdtYjdrcXRwbC1xWXEyS2ROa01YWnRrQn…
EDIT — Frequently Asked Questions
What is the current share price of Editas Medicine, Inc. (EDIT)?
As of 2026-09-07 16:24 PDT, Editas Medicine, Inc. (EDIT) trades at $3.23 on NasdaqGS. Its 52-week range is $1.66 to $4.15.
What is the market capitalisation of EDIT?
Editas Medicine, Inc. (EDIT) has a market capitalisation of $496.06M on NasdaqGS.
What is the P/E ratio of EDIT?
EDIT trades at a trailing price-to-earnings (P/E) ratio of -4.89. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 10.32.
Is EDIT a good stock to buy?
This page provides a data-driven analysis of Editas Medicine, Inc. (EDIT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.